Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Pancreas Cancer Clinical Trials

14 recruiting trials for Pancreas Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
14
Total Trials
14
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGNCT04981119

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect...

Sponsor: A2 Biotherapeutics Inc.Enrolling: 20016 locations
RECRUITINGPhase 1 / Phase 2NCT06051695

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid...

The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC),...

Sponsor: A2 Biotherapeutics Inc.Enrolling: 47412 locations
RECRUITINGPhase 2NCT06229340

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

There is a huge variety of nucleotide substitutions that activate RAS. The search for new "universal" drugs for the RAS pathway that either interfere with RAS upregulation...

Sponsor: N.N. Petrov National Medical Research Center of OncologyEnrolling: 201 location
RECRUITINGNCT07034339

Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution

The intricate interplay between systemic immunity and tumors profoundly influences not only the onset and progression of tumors but also serves as a crucial window into...

Sponsor: First Affiliated Hospital of Zhejiang UniversityEnrolling: 15001 location
RECRUITINGPhase 4NCT05245877

Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery

Thromboprophylaxis for pancreatic surgery can be commenced either preoperatively or postoperatively. Despite a clear trade-off between thrombosis and bleeding in pancreatic...

Sponsor: Helsinki University Central HospitalEnrolling: 8005 locations
RECRUITINGPhase 2NCT07230509

Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate

This randomized controlled trial investigates the safety and efficacy of injecting N-butyl-2- cyanoacrylate (Histoacryl®) into the pancreatic parenchyma during...

Sponsor: Minia UniversityEnrolling: 901 location
RECRUITINGNCT07045571

MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer

Developing a characteristic ctDNA methylation panel for pancreatic ductal adenocarcinoma and establishing an intelligent diagnostic and dynamic monitoring model based on ctDNA...

Sponsor: Yingbin Liu, MD, PhD, FACSEnrolling: 10001 location
RECRUITINGPhase 2NCT05841420

Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer

The aim of the study is to compare the efficacy and toxicity of full-dose Gemcitabine and reduced-dose combination chemotherapy in patients with non-resectable pancreatic cancer,...

Sponsor: Morten LadekarlEnrolling: 981 location
RECRUITINGNCT02775461

Pancreas Registry and High Risk Registry

The purpose of this study is to establish a registry of patients with pancreatic diseases. Patients included in the registry may include those with: pancreatic cancer,...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 13682 locations
RECRUITINGPhase 1 / Phase 2NCT03093688

Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor

Invariant Natural killer T (iNKT) cells are a unique subset of lymphocytes that express homogeneous TCR recognizing KRN7000 which was up-regulated by many kinds of cancer cells....

Sponsor: Shanghai Public Health Clinical CenterEnrolling: 401 location
RECRUITINGPhase 1 / Phase 2NCT07433283

Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor

Independently developed by Sichuan Yingrui Pharmaceutical Technology Co., Ltd., CNSI-Fe is an innovative anti-cancer drug with Fe2+ as the active ingredient, which exerts...

Sponsor: Sichuan Enray Pharmaceutical Sciences CompanyEnrolling: 549 locations
RECRUITINGPhase 2NCT06534762

Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study

This study is an exploratory study, and all the drugs involved are listed drugs. The dosage of mirabetron is selected according to the basis of previous research. The clinical...

Sponsor: Zhejiang Provincial People's HospitalEnrolling: 2601 location
RECRUITINGPhase 1NCT06196294

GPC3/Mesothelin-CAR-γδT Cells Against Cancers

The third generation of GPC3/mesothelin targeted CAR-γδT cells have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies....

Sponsor: Second Affiliated Hospital of Guangzhou Medical UniversityEnrolling: 301 location
RECRUITINGNCT04115254

Stereotactic Magnetic Resonance Guided Radiation Therapy

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients...

Sponsor: Dana-Farber Cancer InstituteEnrolling: 3972 locations